Table 3. LINE-1 methylation level in early-onset colorectal cancer.

Clinical, pathological or molecular features	Total (n)*	Mean	Standard deviation	p-value
Sex
Male	61	60.93	6.598	0.092
Female	54	58.87	6.422
Age
>30 years	91	60.26	6.757	0.345
<30 years	24	58.83	5.791
Body Mass Index (kg/m2)
<30	100	59.71	6.029	0.728
>30	10	60.4	5.337
Family history of CRC1
Yes	16	59.68	6.005	0.246
No	99	61.75	9.40
Tumor location
Rectum	47	58.3	6.54	0.026
Distal to splenic flexure	35	60	5.46
Proximal to splenic flexure	33	62.3	7.12
Synchronous or metachronous CRC
Yes	5	64.2	6.76	0.141
No	110	59.77	6.52
TNM tumor stage
I–II	40	59.63	6.054	0.687
III–IV	75	60.15	6.861
Tumor differentiation
Well or moderate	97	60.03	6.555	0.926
Poor	15	60.2	6.527
Mucinous component
>50%	39	61.41	5.959	0.096
<50%	75	59.24	6.824
Medullary growth pattern
Yes	11	61.36	4.905	0.453
No	103	59.79	6.748
Crohńs reaction
Yes	12	62.75	3.545	0.128
No	98	59.63	6.908
Tumor infiltrating lymphocytes
Yes	26	60.88	5.443	0.447
No	85	59.74	7.004
Microsatellite instability
MSI	25	59.72	6.717	0.454
MSS	90	60.84	6.053
Mismatch repair deficiency2
Yes	27	61.26	6.137	0.244
No	88	59.7	6.680

P value was calculated by t-test.

^*Referred to patients with available information.

¹Including first and second degree relatives.

²MSI-H and/or loss of expression of MMR proteins by immunohistochemistry.